Atlas Trials

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Clinical trial NCT05999149 · RECRUITING

Trial details

NCT number
NCT05999149
Sponsor
Fudan University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
TNBC - Triple-Negative Breast Cancer
Start date
2023-08-20
Primary completion
2025-08-30
Enrollment
424

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.